Actively Recruiting
Study of Fisetins Safety, How It Works in the Body, and Effects on Inflammation in Healthy Adults and Older Patients with Multiple Chronic Conditions
Led by Ove Andersen · Updated on 2026-05-19
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of fisetin, a compound that targets aging cells linked to chronic diseases and inflammation. This clinical trial includes healthy volunteers and older patients with multiple chronic health conditions to understand fisetins absorption, metabolism, safety, and its impact on inflammation, aging cells, and overall health. The study combines Phase 1 and Phase 2a research to gather data for future larger trials. Participants will receive either fisetin at a dose of 20 mgkgday or a placebo for two consecutive days. The trial has two parts an open-label study with healthy volunteers receiving fisetin and a randomized, triple-blind, placebo-controlled study with older patients receiving fisetin or placebo. Both groups will undergo three sub-studies focusing on pharmacokinetics, safety, and evaluation of potential health outcomes related to aging and inflammation. During the study, participants will be assessed at various time points over about three months. Researchers will monitor fisetin levels, adverse events, inflammation markers, aging biomarkers, physical and cognitive functions, and quality of life. Measurements include blood tests, frailty indexes, and cognitive assessments to evaluate the treatments effects and safety. The study aims to identify meaningful outcomes for future research and ensure participant well-being throughout the trial.
CONDITIONS
Brief Title
Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity
Research Team
J
Juliette Tavenier
L
Line Jee Hartmann Rasmussen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here